Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-02-05T09:26:29+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

Dimerix a Winner of Westpac’s Businesses of Tomorrow Program

Dimerix is incredibly proud to have been named as a 2018 winner of the Westpac 200 Businesses of Tomorrow program in The [...]

ASX: Dimerix Secures Ethics Approval

Dimerix is pleased to announce ethics approval for DMX-200 Phase 2 trials for Diabetic Kidney Disease (DKD) and Focal Segmental Glomerulosclerosis [...]

Dimerix Recommended as Stock To Watch

Investment Manager Tony Locantro from Alto Capital has recommended Dimerix stock as a good investment on his Bulls, Bears and Brokers [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates